Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Michigan: - Veteran's Administration Medical Center - Ann Arbor — Ann Arbor, Michigan
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- McLaren Cancer Institute-Bay City — Bay City, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Michigan: - Saint Joseph Mercy Hospital — Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Saint Joseph Mercy Brighton — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Saint Joseph Mercy Canton — Canton, Michigan
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Michigan: - Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
- OSF Saint Francis Hospital and Medical Group — Escanaba, Michigan
- Genesys Hurley Cancer Institute — Flint, Michigan
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
- Henry Ford Medical Center-Fairlane — Dearborn, Michigan
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Michigan: - Michigan Institute of Urology, PC — Troy, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Michigan: - Henry Ford Hospital ( Site 0015) — Detroit, Michigan
- Cancer and Hematology Centers of Western Michigan ( Site 0005) — Grand Rapids, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Michigan: - University of Michigan Health System — Ann Arbor, Michigan
- Henry Ford Cancer Detroit — Detroit, Michigan
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Michigan: - Henry Ford Hospital ( Site 0015) — Detroit, Michigan
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Michigan: - BAMF Health — Grand Rapids, Michigan
- Corewell Health — Grand Rapids, Michigan
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Michigan: - VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, Michigan
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Michigan: - Henry Ford Health — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Phase 2 Recruiting Industry
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine us…
Sponsor: Monte Rosa Therapeutics, Inc
NCT ID: NCT07745361
Sites in Michigan: - Henry Ford — Novi, Michigan
Phase 2 Recruiting Industry
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…
Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in Michigan: - VA Ann Arbor Healthcare System — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06863272
Sites in Michigan: - University of Michigan ( Site 0021) — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 …
Sponsor: AstraZeneca
NCT ID: NCT07192614
Sites in Michigan: - Research Site — Grand Rapids, Michigan
Phase 2 Recruiting Industry
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.
Sponsor: Syntrix Biosystems, Inc.
NCT ID: NCT06228053
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing h…
Sponsor: University of British Columbia
NCT ID: NCT04812366
Sites in Michigan: - University of Michigan Health — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Sponsor: GlaxoSmithKline
NCT ID: NCT07332455
Sites in Michigan: - GSK Investigational Site — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…
Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Michigan: - BAMF Health — Grand Rapids, Michigan
Phase 2 Recruiting Federal
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and …
Sponsor: VA Office of Research and Development
NCT ID: NCT06084338
Sites in Michigan: - VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resis…
Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT06616155
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Karmanos Cancer Institute — Detroit, Michigan